Blood sample as a promising diagnostic tool in oncology - literature review
DOI:
https://doi.org/10.12775/JEHS.2023.42.01.001Keywords
ctDNA, circulating tumor DNA, CTC, liquid biopsy, tumor, cancerAbstract
Introduction
Cancer is one of the leading causes of death worldwide. The molecular characterization of solid tumors has provided significant advances in oncology, and genome profiling using circulating tumor DNA (ctDNA) has helped improve the quality of medical care for patients with cancer. Liquid biopsy is a diagnostic molecular test to demonstrate the presence of circulating tumor DNA or circulating tumor cells released from primary or metastatic solid tumors. In addition, the minimally invasive nature of the liquid biopsy enables quick verification of the grade of malignancy. Observation of ctDNA in blood tests is of great importance at the treatment stage, it allows to determine resistance to the applied treatment, response to therapy and to predict relapse before it occurs.
Aim of the study
The aim of this review is to present information on the use of circulating tumor DNA together with circulating tumor cells in oncological diagnostics.
Materials and methods
The work was created based on the PubMed database. Articles were searched in English using the following keywords: ctDNA, CTC, cfDNA.
Results
Currently, ctDNA analysis is an alternative to traditional molecular diagnostics of cancer tissue, assessment of the effectiveness of therapy, monitoring of tumor dynamics, monitoring of progression and predicting recurrence.
Summary
There are not many diagnostic methods for detecting ctDNA. Due to the short length of the fragments and the low content in the samples, ctDNA analysis requires more sensitive techniques to ensure its reliability compared to methods used in solid tissue biopsies. Existing techniques of ctDNA analysis focus mainly on the identification of mutations in advanced stages of cancer, less often on early diagnosis.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin [Internet]. 2018;68(1):7–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29313949
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin [Internet]. 2021 Mar;71(2):176–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33165928
Davis AA, Iams WT, Chan D, Oh MS, Lentz RW, Peterman N, et al. Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Mol Cancer Ther [Internet]. 2020;19(7):1486–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32371589
Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget [Internet]. 2016 Jul 26;7(30):48832–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27223063
MANDEL P, METAIS P. Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil [Internet]. 1948 Feb;142(3–4):241–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18875018
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res [Internet]. 1977 Mar;37(3):646–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18875018
Aghamir SMK, Heshmat R, Ebrahimi M, Khatami F. Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors. Epigenet Insights [Internet]. 2020;13:2516865720904052. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32166219
Macías M, Alegre E, Díaz-Lagares A, Patiño A, Pérez-Gracia JL, Sanmamed M, et al. Liquid Biopsy: From Basic Research to Clinical Practice. Adv Clin Chem [Internet]. 83:73–119. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29304904
Neoh KH, Hassan AA, Chen A, Sun Y, Liu P, Xu KF, et al. Rethinking liquid biopsy: Microfluidic assays for mobile tumor cells in human body fluids. Biomaterials [Internet]. 2018 Jan;150:112–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29035737
ASHWORTH T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J [Internet]. 1869;14:146. Available from: http://ci.nii.ac.jp/naid/10027663080/en/
KNISELY WH, MAHALEY MS. Relationship between size and distribution of spontaneous metastases and three sizes of intravenously injected particles of VX2 carcinoma. Cancer Res [Internet]. 1958 Sep;18(8 Part 1):900–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13573362
Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res [Internet]. 1974 May;34(5):997–1004. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4841969
Wang L, Li Y, Xu J, Zhang A, Wang X, Tang R, et al. Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett [Internet]. 2018;412:99–107. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29031565
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Crit Rev Oncol Hematol [Internet]. 2019 Feb;134:39–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30771872
Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther [Internet]. 2021 Nov 22;6(1):404. Available from: https://www.nature.com/articles/s41392-021-00817-8
Shen Z, Wu A, Chen X. Current detection technologies for circulating tumor cells. Chem Soc Rev [Internet]. 2017;46(8):2038–56. Available from: http://xlink.rsc.org/?DOI=C6CS00803H
Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology [Internet]. 2021 Sep;32(9):1167–77. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753421020469
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep;14(9):985–90.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 2014 Feb;6(224):224ra24-224ra24.
Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, et al. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med. 2017 Jun;141(6):751–8.
Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). The Journal of Molecular Diagnostics. 2015 May;17(3):251–64.
Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, et al. Urine as a Source of Liquid Biopsy for Cancer. Cancers (Basel) [Internet]. 2021 May 28;13(11):2652. Available from: https://www.mdpi.com/2072-6694/13/11/2652
Escudero L, Martínez-Ricarte F, Seoane J. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Cancers (Basel) [Internet]. 2021 Apr 21;13(9):1989. Available from: https://www.mdpi.com/2072-6694/13/9/1989
Boyer M, Cayrefourcq L, Dereure O, Meunier L, Becquart O, Alix-Panabières C. Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. Cancers (Basel) [Internet]. 2020 Apr 13;12(4). Available from: http://www.ncbi.nlm.nih.gov/pubmed/32295074
Chen X, Wang L, Lou J. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review. Med Sci Monit [Internet]. 2020 Mar 22;26:e921040. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32200389
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Dominik Drobek, Kacper Wojtala, Michał Turek, Aleksandra Winiarz, Paula Szlendak, Katarzyna Toś, Katarzyna Wąsala, Sylwia Grosman, Agata Węgrzyniak, Wojciech Wokurka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 890
Number of citations: 0
